InsiderTrades

Form 4 for EDIT Editas Medicine, Inc.

Accepted 2024-03-05 00:00:00 ET · period of report 2024-03-02 · accession 0001650664-24-000015 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2024-03-05 2024-03-02 EDIT O'Neill Gilmore Neil CEO, Dir A - Grant $0.00 +275.1K 260.9K New $0
D 2024-03-05 2024-03-05 EDIT O'Neill Gilmore Neil CEO, Dir S - Sale $9.42 -77.8K 327.5K -19% -$733.1K
D 2024-03-05 2024-03-02 EDIT O'Neill Gilmore Neil CEO, Dir A - Grant $0.00 +392.1K 392.1K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-03-02 A A 72,212 $0.00 405,294 D — —
2 Common Common Stock 2024-03-05 S D 77,824 $9.42 327,470 D — — (F5) This transaction was executed in multiple trades at prices ranging from $9.1036 to $9.4298. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
3 Common Common Stock 2024-03-02 A A 72,213 $0.00 333,082 D — —
4 Common Common Stock 2024-03-02 A A 130,700 $0.00 260,869 D — —
5 Derivative Stock Option (right to buy) 2024-03-02 A A 392,100 $0.00 392,100 D $10.53 · — to 2034-03-01 392,100 Common Stock (F6) This option was granted on March 2, 2024 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2024 through March 2, 2028.